pALD-AAV System

pALD-AAV System Overview

Recombinant AAV (rAAV) manufacturing is composed of four main components which include a rep/cap plasmid, a helper plasmid, a transgene plasmid, and a viral packaging cell line. Triple transfection of the three plasmids into HEK293 cells is the most frequently used rAAV production method.

Benefits of pALD-AAV

  • Royalty free, including for commercial products
  • Kanamycin resistance
  • Consistent, reliable supply
  • Immediately available at research grade
pALD AAV System Process Illustration

pALD-HELP Plasmid

In stock, royalty-free, helper plasmid solution for recombinant AAV manufacturing.



Learn More

pALD-X80 Plasmid

In stock, royalty-free, helper plasmid solution for recombinant AAV manufacturing.



Learn More

Rep/Cap Plasmids

Our rep/cap plasmids provide the appropriate packaging functions for AAV-based gene therapeutics.



Learn more

Custom Manufacturing

Order custom products with different buffers, concentrations, and more.



Get Started

Related News

Aldevron Now Offering pALD-HELP Plasmids for Viral Vector Production

Aldevron announced today it is now offering pALD-HELP to support AAV viral vector manufacturing. This additional Ad helper plasmid is immediately...

In the News: AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the...

In the News: Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality...

Related Blog Posts

The Pivotal Role of Plasmid DNA

Plasmid DNA has historically been key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of...

Plasmid DNA Insights: Expanded Focus on CMC in Gene & Cell Therapy Development

Aldevron recently hosted a webinar through Endpoints news titled: Plasmid DNA Insights: Expanded Focus on CMC in Gene and Cell Therapy Development....

DNA Plasmids for the Genetic Engineering of Clinical-Grade T Cells

Our inaugural presentation for the Breakthrough Speaker Series is Dr. Laurence Cooper, on behalf of ZioPharm Oncology, presenting "DNA Plasmids for...